The topic Embryonal Tumor with Abundant Neuropil and True Rosettes you are seeking is a synonym, or alternative name, or is closely related to the medical condition Embryonal Tumor with Multilayered Rosettes, C19MC Altered.

Quick Summary:

• An embryonal tumor is a type of brain tumor. A brain tumor may be described as a mass of abnormally growing cells arising from the brain tissue (brain parenchyma and meninges) or the spinal cord (central spine). The brain along-with the spinal cord constitute the central nervous system (CNS) of the body
• Broadly, brain tumors are classified as benign (non-cancerous) and malignant. Malignant tumors are cancerous and can spread or metastasize to other regions of the body. They generally exhibit rapid growth and, in some cases, may present symptoms during the early stages of development
• The World Health Organization (WHO) classifies central nervous system tumors according to their grade and histological subtypes. A tumor subtype is determined by a pathologist after examining a tissue biopsy of the tumor under the microscope. This WHO classification system is used by healthcare professionals all over the world in diagnosing and treating these tumors
• Embryonal Tumor with Multilayered Rosettes, C19MC Altered is a highly uncommon and highly aggressive brain tumor that almost exclusively occurs in young children. This high-grade malignancy may be found anywhere in the brain but is commonly diagnosed at supratentorial locations, typically involving the cerebral hemispheres. By definition, the tumor is characterized by C19MC alteration at chromosome locus 19q13.42 (termed C19MC amplification) that is identified through molecular studies
• Embryonal Tumor with Multilayered Rosettes (EMTR) is a recently classified tumor by the WHO. Earlier, this tumor was variously described among the scientific community as Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma, and as a type of medulloepithelioma. However, presently, these terminologies are no longer in use. Also, irrespective of the histological subtyping, any pediatric central nervous system tumor presenting C19MC amplification is now called EMTR, C19MC-Altered
• According to WHO, Embryonal Tumor with Multilayered Rosettes is part of a group designated “embryonal tumors”, which are all high-grade malignancies. It is a histologic subtype of a primitive neuroectodermal tumor (PNET). High-grade tumors are known to exhibit aggressive behavior and grow rapidly. These tumors are known to infiltrate widely and destroy tissues, causing necrosis. They are also known to recur sooner following treatment
• The cause of formation of Embryonal Tumor with Multilayered Rosettes, C19MC Altered is not well-established. It is reported that a combination of several factors may play a role in their formation, including genetic, environmental, and lifestyle-related. The risk factors may include presence of certain genetic disorders, exposure to ionized radiation, viral infections, and head trauma
• The signs and symptoms of Embryonal Tumor with Multilayered Rosettes, C19MC Altered depend on the location of the tumor. Individuals may experience headaches, weakness in different parts of the body, convulsions, vision and speech disturbances. Large-sized tumors may compress adjacent brain tissue resulting in complications. Metastatic tumors may spread outside the brain and spinal cord
• The treatment modalities for Embryonal Tumor with Multilayered Rosettes, C19MC Altered may include a combination of surgery, radiation therapy, and chemotherapy. The prognosis is determined by a wide variety of factors, such as age of the individual, tumor size, and overall health status. Nevertheless, the prognosis is extremely poor, since it is an aggressive malignancy with metastatic potential

Please find comprehensive information on Embryonal Tumor with Multilayered Rosettes, C19MC Altered regarding definition, distribution, risk factors, causes, signs & symptoms, diagnosis, complications, treatment, prevention, prognosis, and additional useful information HERE.